In patients with Alzheimer disease who undergo routine care, the use of cholinesterase inhibitors (versus non-use) was reported to be associated with a lower risk of CKD progression [47]. This evidence concerns the gene BCHE and early-onset autosomal dominant Alzheimer disease.